Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Malaysian Genomics Resource Centre Bhd has the Profitability Rank of 4.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is rated on a scale of 1 to 10 and is based on these factors:
1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.
Malaysian Genomics Resource Centre Bhd Profitability Rank Related Terms
XKLS:0155 vs TMO, DHR, IDXX: Profitability Rank Comparison
For the Diagnostics & Research subindustry, Malaysian Genomics Resource Centre Bhd's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Malaysian Genomics Resource Centre Bhd Profitability Rank vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Malaysian Genomics Resource Centre Bhd's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Malaysian Genomics Resource Centre Bhd's Profitability Rank falls into.
Malaysian Genomics Resource Centre Bhd Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The rank is rated on a scale of 1 to 10. A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.
Malaysian Genomics Resource Centre Bhd has the Profitability Rank of 4.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Malaysian Genomics Resource Centre Bhd (XKLS:0155) has a Profitability Rank of 4 as of Mar. 2026. Profitability and Growth ranks a company based on its profit margins and earnings growth. View historical data on Malaysian Genomics Resource Centre Bhd and its competitors. This is 100% above median its historical median of 2.00. Over the past decade, Malaysian Genomics Resource Centre Bhd's Profitability Rank has ranged from 1.00 to 7.00.
Is Malaysian Genomics Resource Centre Bhd's Profitability Rank too high?
Malaysian Genomics Resource Centre Bhd's current Profitability Rank of 4 is 100% above median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 7.00. Overall, Malaysian Genomics Resource Centre Bhd has a GF Score™ of 48/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Malaysian Genomics Resource Centre Bhd's Profitability Rank compare to TMO and DHR?
Malaysian Genomics Resource Centre Bhd's Profitability Rank of 4 can be compared against companies in the Medical Diagnostics & Research industry. Historically, Malaysian Genomics Resource Centre Bhd's own Profitability Rank has ranged from 1.00 to 7.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Profitability Rank for a Medical Diagnostics & Research company?
A good Profitability Rank depends on the Medical Diagnostics & Research industry context. However, Profitability Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Profitability Rank mean?
A high Profitability Rank can signal that a stock is expensive relative to its fundamentals. Profitability and Growth ranks a company based on its profit margins and earnings growth. View historical data on Malaysian Genomics Resource Centre Bhd and its competitors. Malaysian Genomics Resource Centre Bhd's current Profitability Rank is 4, which is 100% above median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Malaysian Genomics Resource Centre Bhd stock overvalued right now?
Based on GuruFocus' analysis, Malaysian Genomics Resource Centre Bhd (XKLS:0155) is currently considered Modestly Overvalued. The stock's GF Value™ is RM0.31, compared to a current price of RM0.38 — trading 22.6% above its estimated fair value. The current Profitability Rank is 4, which is 100% above median its 10-year median of 2.00. Malaysian Genomics Resource Centre Bhd's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Profitability Rank calculated?
Profitability Rank is calculated from a company's financial statements. For Malaysian Genomics Resource Centre Bhd (XKLS:0155), the current Profitability Rank is 4 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Malaysian Genomics Resource Centre Bhd (XKLS:0155) Overvalued in 2026?
Based on GuruFocus' analysis, Malaysian Genomics Resource Centre Bhd stock appears to be overvalued.
The current stock price of RM0.38 is trading 22.6% above its estimated GF Value™ of RM0.31.
GuruFocus considers Malaysian Genomics Resource Centre Bhd to be Modestly Overvalued.
Key valuation signals for XKLS:0155:
Profitability Rank: 4 (100% above median its 10-year median of 2.00)
GF Value™: RM0.31 vs. price of RM0.38 (22.6% above fair value)
No single metric tells the full story. See the XKLS:0155 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Malaysian Genomics Resource Centre Bhd is a Malaysia-based company. The company's principal activities include enabling personalized and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services, as well as investment holding. It offers genome sequencing and analysis (GSA) services and genetic screening services (GSS). The group offerings include precision genetic screening, project-based analysis, and high-quality cell therapy and cosmeceutical products. The reportable segments of the Group derive their revenue from the provision of personalised and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services within the healthcare segment.
48GF Score
Get the complete analysis for XKLS:0155
Profitability Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0155 has been successfully added to your 
